Denali Therapeutics Inc. (DNLI) Cash Flow Statement
Denali Therapeutics Inc. (DNLI) generated -$434.0M of operating cash flow over the twelve months to 2026-06-30, spent $3.4M on capital expenditure and had free cash flow of -$437.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNLIDenali Therapeutics Inc.Follow DNLI — free
—
Price chart with a free account
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.05 | -0.15 | 0.42 | -0.21 | -0.24 | -0.36 | -0.35 | -0.41 | -0.43 | |
| Capital expenditure | 0.00 | 0.02 | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | -0.00 | |
| Free cash flow | 0.05 | -0.17 | 0.41 | -0.22 | -0.26 | -0.37 | -0.36 | -0.42 | -0.44 | |
| Stock-based compensation | 0.02 | 0.04 | 0.05 | 0.09 | 0.10 | 0.11 | 0.10 | 0.10 | — |
USD billions · SEC XBRL
Denali Therapeutics Inc. — questions
- What is Denali Therapeutics Inc.'s operating cash flow?
- -$434.0M over the twelve months to 2026-06-30.
- How much does Denali Therapeutics Inc. spend on capital expenditure?
- $3.4M over the twelve months to 2026-06-30.
- What is Denali Therapeutics Inc.'s free cash flow?
- -$437.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Denali Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.